{"name":"Sun Pharmaceutical Industries","slug":"sun-pharma","ticker":"SUNPHARMA.NS","exchange":"NSE","domain":"sunpharma.com","description":"Sun Pharmaceutical Industries Limited is an Indian multinational pharmaceutical company headquartered in Mumbai. It manufactures and sells pharmaceutical formulations and active pharmaceutical ingredients (APIs) in more than 100 countries. It is the largest pharmaceutical company in India and the fourth largest specialty generic pharmaceutical company in the world.","hq":"Mumbai, India","founded":1983,"employees":"43000","ceo":"Dilip Shanghvi","sector":"Specialty Pharma / Generics","stockPrice":1714.6,"stockChange":-3.4,"stockChangePercent":-0.2,"marketCap":"$4.1T","metrics":{"revenue":568090886144,"revenueGrowth":13.5,"grossMargin":78.5,"rdSpend":0,"netIncome":109152698368,"cash":278804299776,"dividendYield":0.97,"peRatio":37.7,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"1974-01-01","label":"Halog first approved","drug":"Halog","drugSlug":"halcinonide","type":"approval","sentiment":"positive"},{"date":"1978-01-01","label":"Westcort first approved","drug":"Westcort","drugSlug":"hydrocortisone-valerate","type":"approval","sentiment":"positive"},{"date":"1985-01-01","label":"Lac-Hydrin first approved","drug":"Lac-Hydrin","drugSlug":"ammonium-lactate","type":"approval","sentiment":"positive"},{"date":"1999-01-01","label":"Levulan first approved","drug":"Levulan","drugSlug":"aminolevulinic-acid","type":"approval","sentiment":"positive"},{"date":"2006-01-01","label":"Dacogen first approved","drug":"Dacogen","drugSlug":"decitabine","type":"approval","sentiment":"positive"},{"date":"2020-01-01","label":"Winlevi first approved","drug":"Winlevi","drugSlug":"clascoterone","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2025-06-01","label":"Loratadine patent cliff ($150.0M at risk)","drug":"Loratadine","type":"patent_expiry","sentiment":"negative"},{"date":"2027-06-01","label":"Levocetirizine patent cliff ($200.0M at risk)","drug":"Levocetirizine","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":18,"colorKey":"cardiovascular","drugs":[{"name":"Desoximetasone 0.05% twice daily","genericName":"Desoximetasone 0.05% twice daily","slug":"desoximetasone-0-05-twice-daily","indication":"Other","status":"phase_2"},{"name":"Desoximetasone 0.25% once daily","genericName":"Desoximetasone 0.25% once daily","slug":"desoximetasone-0-25-once-daily","indication":"Other","status":"phase_2"},{"name":"GL0034 Dose Level 4","genericName":"GL0034 Dose Level 4","slug":"gl0034-dose-level-4","indication":"Other","status":"phase_2"},{"name":"Malathion gel 0.5%","genericName":"Malathion gel 0.5%","slug":"malathion-gel-0-5","indication":"Head lice infestation (pediculosis capitis)","status":"phase_3"},{"name":"Ovide (malathion) lotion 0.05%","genericName":"Ovide (malathion) lotion 0.05%","slug":"ovide-malathion-lotion-0-05","indication":"Treatment of head lice infestations","status":"phase_3"},{"name":"Ruxolitinib Topical Cream 1.5%","genericName":"Ruxolitinib Topical Cream 1.5%","slug":"ruxolitinib-topical-cream-1-5","indication":"Other","status":"phase_1"},{"name":"Topical TA-102 D","genericName":"Topical TA-102 D","slug":"topical-ta-102-d","indication":"Other","status":"phase_1"},{"name":"Bromday™","genericName":"Bromday™","slug":"bromday","indication":"Other","status":"marketed"},{"name":"GL0034 Dose Level 2","genericName":"GL0034 Dose Level 2","slug":"gl0034-dose-level-2","indication":"Other","status":"phase_2"},{"name":"GL0034 Dose Level 6","genericName":"GL0034 Dose Level 6","slug":"gl0034-dose-level-6","indication":"Other","status":"phase_2"},{"name":"Lac-Hydrin","genericName":"AMMONIUM LACTATE","slug":"ammonium-lactate","indication":"Ichthyosis vulgaris","status":"marketed"},{"name":"Levulan","genericName":"AMINOLEVULINIC ACID","slug":"aminolevulinic-acid","indication":"Actinic keratosis","status":"marketed"},{"name":"Lotrimin Ultra®","genericName":"Lotrimin Ultra®","slug":"lotrimin-ultra","indication":"Tinea pedis (athlete's foot)","status":"marketed"},{"name":"MM-II dose I","genericName":"MM-II dose I","slug":"mm-ii-dose-i","indication":"Other","status":"phase_2"},{"name":"Permethrin 1% rinse","genericName":"Permethrin 1% rinse","slug":"permethrin-1-rinse","indication":"Treatment and prevention of head lice infestations","status":"phase_3"},{"name":"Placebo topical cream","genericName":"Placebo topical cream","slug":"placebo-topical-cream","indication":"Other","status":"marketed"},{"name":"TA103","genericName":"TA103","slug":"ta103","indication":"Other","status":"phase_1"},{"name":"matching placebo injections","genericName":"matching placebo injections","slug":"matching-placebo-injections","indication":"Comparing the efficacy of a new drug to a placebo","status":"phase_3"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":6,"colorKey":"neuroscience","drugs":[{"name":"Desoximetasone Spray 0.25%","genericName":"Desoximetasone Spray 0.25%","slug":"desoximetasone-spray-0-25","indication":"Inflammatory and pruritic dermatoses responsive to topical corticosteroids (e.g., eczema, psoriasis, dermatitis)","status":"marketed"},{"name":"TILD","genericName":"TILD","slug":"tild","indication":"Plaque psoriasis","status":"marketed"},{"name":"ADPS topical product","genericName":"ADPS topical product","slug":"adps-topical-product","indication":"Psoriasis","status":"phase_2"},{"name":"DSXS topical product","genericName":"DSXS topical product","slug":"dsxs-topical-product","indication":"Seborrheic dermatitis","status":"phase_2"},{"name":"Halobetasol Topical Lotion","genericName":"Halobetasol Topical Lotion","slug":"halobetasol-topical-lotion","indication":"Inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses","status":"marketed"},{"name":"Injections of tildrakizumab","genericName":"Injections of tildrakizumab","slug":"injections-of-tildrakizumab","indication":"Moderate to severe plaque psoriasis","status":"marketed"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"oncology","drugs":[{"name":"Dacogen","genericName":"decitabine","slug":"decitabine","indication":"Acute myeloid leukemia, disease","status":"marketed"},{"name":"Halog","genericName":"HALCINONIDE","slug":"halcinonide","indication":"Atopic dermatitis","status":"marketed"},{"name":"ISV-303","genericName":"ISV-303","slug":"isv-303","indication":"Cancer (specific indication under clinical evaluation in Phase 3)","status":"phase_3"},{"name":"ISV-305","genericName":"ISV-305","slug":"isv-305","indication":"Oncology indication (specific indication not publicly confirmed)","status":"phase_3"}]},{"name":"Dermatology","slug":"dermatology","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"infectious","drugs":[{"name":"Winlevi","genericName":"CLASCOTERONE","slug":"clascoterone","indication":"Acne vulgaris","status":"marketed"},{"name":"DSXS topical","genericName":"DSXS topical","slug":"dsxs-topical","indication":"Dermatological indication (specific indication not publicly disclosed)","status":"phase_3"},{"name":"Onexton™ Gel","genericName":"Onexton™ Gel","slug":"onexton-gel","indication":"Acne vulgaris","status":"phase_3"},{"name":"Westcort","genericName":"HYDROCORTISONE VALERATE","slug":"hydrocortisone-valerate","indication":"Corticosteroid-responsive dermatoses","status":"marketed"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"DSXS","genericName":"DSXS","slug":"dsxs","indication":"Type 2 diabetes","status":"phase_3"},{"name":"SPIL1033","genericName":"SPIL1033","slug":"spil1033","indication":"Type 2 diabetes","status":"phase_3"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"respiratory","drugs":[{"name":"Zero-dose","genericName":"Zero-dose","slug":"zero-dose","indication":"COVID-19 prevention","status":"phase_3"},{"name":"Naftifine Hydrochloride Cream 2%","genericName":"Naftifine Hydrochloride Cream 2%","slug":"naftifine-hydrochloride-cream-2","indication":"Tinea pedis (athlete's foot)","status":"phase_3"}]},{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"ophthalmology","drugs":[{"name":"PART 1: Double-blind Placebo-controlled","genericName":"PART 1: Double-blind Placebo-controlled","slug":"part-1-double-blind-placebo-controlled","indication":"Major depressive disorder","status":"phase_3"},{"name":"SAPHRIS","genericName":"SAPHRIS","slug":"saphris","indication":"Schizophrenia","status":"marketed"}]},{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"rare","drugs":[{"name":"Brinzolamide ophthalmic suspension","genericName":"Brinzolamide ophthalmic suspension","slug":"brinzolamide-ophthalmic-suspension","indication":"Elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma","status":"phase_3"}]},{"name":"Ophthalmology","slug":"ophthalmology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"metabolic","drugs":[{"name":"OTX-101 0.09%","genericName":"OTX-101 0.09%","slug":"otx-101-0-09","indication":"Treatment of dry eye disease","status":"phase_3"}]}],"pipeline":[{"name":"Dacogen","genericName":"decitabine","slug":"decitabine","phase":"marketed","mechanism":"Dacogen works by inhibiting the enzyme that adds methyl groups to DNA, which helps to restore normal gene function in cancer cells.","indications":["Acute myeloid leukemia, disease","Myelodysplastic syndrome"],"catalyst":""},{"name":"DSXS","genericName":"DSXS","slug":"dsxs","phase":"phase_3","mechanism":"DSXS is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"Desoximetasone 0.05% twice daily","genericName":"Desoximetasone 0.05% twice daily","slug":"desoximetasone-0-05-twice-daily","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Desoximetasone 0.25% once daily","genericName":"Desoximetasone 0.25% once daily","slug":"desoximetasone-0-25-once-daily","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Desoximetasone Spray 0.25%","genericName":"Desoximetasone Spray 0.25%","slug":"desoximetasone-spray-0-25","phase":"marketed","mechanism":"Desoximetasone is a topical corticosteroid that suppresses inflammatory and immune responses in the skin by binding to glucocorticoid receptors.","indications":["Inflammatory and pruritic dermatoses responsive to topical corticosteroids (e.g., eczema, psoriasis, dermatitis)"],"catalyst":""},{"name":"GL0034 Dose Level 4","genericName":"GL0034 Dose Level 4","slug":"gl0034-dose-level-4","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Malathion gel 0.5%","genericName":"Malathion gel 0.5%","slug":"malathion-gel-0-5","phase":"phase_3","mechanism":"Malathion is an organophosphate insecticide that inhibits acetylcholinesterase, causing accumulation of acetylcholine and paralysis of parasites.","indications":["Head lice infestation (pediculosis capitis)","Scabies (Sarcoptes scabiei infestation)"],"catalyst":""},{"name":"Ovide (malathion) lotion 0.05%","genericName":"Ovide (malathion) lotion 0.05%","slug":"ovide-malathion-lotion-0-05","phase":"phase_3","mechanism":"Ovide (malathion) lotion works by killing lice and their eggs on the scalp.","indications":["Treatment of head lice infestations"],"catalyst":""},{"name":"Ruxolitinib Topical Cream 1.5%","genericName":"Ruxolitinib Topical Cream 1.5%","slug":"ruxolitinib-topical-cream-1-5","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"TILD","genericName":"TILD","slug":"tild","phase":"marketed","mechanism":"Tild is a small molecule that works by interacting with a specific target in the body.","indications":["Plaque psoriasis"],"catalyst":""},{"name":"Topical TA-102 D","genericName":"Topical TA-102 D","slug":"topical-ta-102-d","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Winlevi","genericName":"CLASCOTERONE","slug":"clascoterone","phase":"marketed","mechanism":"Winlevi works by blocking the androgen receptor, a protein that helps regulate hormones in the body.","indications":["Acne vulgaris"],"catalyst":""},{"name":"Zero-dose","genericName":"Zero-dose","slug":"zero-dose","phase":"phase_3","mechanism":"Zero-dose is a vaccine candidate that uses a novel approach to stimulate an immune response without the need for a traditional vaccine dose.","indications":["COVID-19 prevention"],"catalyst":""},{"name":"ADPS topical product","genericName":"ADPS topical product","slug":"adps-topical-product","phase":"phase_2","mechanism":"ADPS topical product is a small molecule that targets the skin to treat various conditions.","indications":["Psoriasis"],"catalyst":""},{"name":"Brinzolamide ophthalmic suspension","genericName":"Brinzolamide ophthalmic suspension","slug":"brinzolamide-ophthalmic-suspension","phase":"phase_3","mechanism":"Brinzolamide is a carbonic anhydrase inhibitor that reduces aqueous humor production in the eye, thereby lowering intraocular pressure.","indications":["Elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma"],"catalyst":""},{"name":"Bromday™","genericName":"Bromday™","slug":"bromday","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"DSXS topical","genericName":"DSXS topical","slug":"dsxs-topical","phase":"phase_3","mechanism":"DSXS is a topical formulation designed to deliver active pharmaceutical ingredients to skin lesions or dermatological conditions through enhanced penetration.","indications":["Dermatological indication (specific indication not publicly disclosed)"],"catalyst":""},{"name":"DSXS topical product","genericName":"DSXS topical product","slug":"dsxs-topical-product","phase":"phase_2","mechanism":"DSXS topical product is a corticosteroid that reduces inflammation and itching by suppressing the immune system.","indications":["Seborrheic dermatitis","Psoriasis"],"catalyst":""},{"name":"GL0034 Dose Level 2","genericName":"GL0034 Dose Level 2","slug":"gl0034-dose-level-2","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"GL0034 Dose Level 6","genericName":"GL0034 Dose Level 6","slug":"gl0034-dose-level-6","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Halobetasol Topical Lotion","genericName":"Halobetasol Topical Lotion","slug":"halobetasol-topical-lotion","phase":"marketed","mechanism":"Halobetasol is a potent topical corticosteroid that suppresses inflammatory and immune responses in the skin by binding to glucocorticoid receptors.","indications":["Inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses","Severe dermatitis, psoriasis, and lichen planus (topical)"],"catalyst":""},{"name":"Halog","genericName":"HALCINONIDE","slug":"halcinonide","phase":"marketed","mechanism":"Glucocorticoid receptor","indications":["Atopic dermatitis","Contact dermatitis","Discoid lupus erythematosus","Eruption of skin","Granuloma annulare"],"catalyst":""},{"name":"ISV-303","genericName":"ISV-303","slug":"isv-303","phase":"phase_3","mechanism":"ISV-303 is an investigational immunotherapy designed to enhance anti-tumor immune responses through modulation of the immune checkpoint pathway.","indications":["Cancer (specific indication under clinical evaluation in Phase 3)"],"catalyst":""},{"name":"ISV-305","genericName":"ISV-305","slug":"isv-305","phase":"phase_3","mechanism":"ISV-305 is an investigational immunotherapy designed to enhance anti-tumor immune responses through modulation of the immune checkpoint pathway.","indications":["Oncology indication (specific indication not publicly confirmed)"],"catalyst":""},{"name":"Injections of tildrakizumab","genericName":"Injections of tildrakizumab","slug":"injections-of-tildrakizumab","phase":"marketed","mechanism":"Tildrakizumab is a monoclonal antibody that selectively blocks interleukin-23 (IL-23) to reduce inflammatory immune responses in the skin.","indications":["Moderate to severe plaque psoriasis","Psoriatic arthritis"],"catalyst":""},{"name":"Lac-Hydrin","genericName":"AMMONIUM LACTATE","slug":"ammonium-lactate","phase":"marketed","mechanism":"Small molecule","indications":["Ichthyosis vulgaris","Xerosis"],"catalyst":""},{"name":"Levulan","genericName":"AMINOLEVULINIC ACID","slug":"aminolevulinic-acid","phase":"marketed","mechanism":"Levulan accumulates in abnormal skin cells, allowing for visualization and treatment.","indications":["Actinic keratosis","Fluorescent stain","Non-Hyperkeratotic Actinic Keratoses"],"catalyst":""},{"name":"Lotrimin Ultra®","genericName":"Lotrimin Ultra®","slug":"lotrimin-ultra","phase":"marketed","mechanism":"Lotrimin Ultra contains butenafine, an allylamine antifungal that disrupts fungal cell membrane synthesis by inhibiting squalene epoxidase.","indications":["Tinea pedis (athlete's foot)","Tinea cruris (jock itch)","Tinea corporis (ringworm)","Tinea versicolor"],"catalyst":""},{"name":"MM-II dose I","genericName":"MM-II dose I","slug":"mm-ii-dose-i","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Naftifine Hydrochloride Cream 2%","genericName":"Naftifine Hydrochloride Cream 2%","slug":"naftifine-hydrochloride-cream-2","phase":"phase_3","mechanism":"Naftifine is a fungistatic agent that inhibits fungal sterol synthesis by blocking squalene epoxidase, disrupting the fungal cell membrane.","indications":["Tinea pedis (athlete's foot)","Tinea cruris (jock itch)","Tinea corporis (ringworm)","Other dermatophyte infections"],"catalyst":""},{"name":"OTX-101 0.09%","genericName":"OTX-101 0.09%","slug":"otx-101-0-09","phase":"phase_3","mechanism":"OTX-101 is a topical ophthalmic solution used to treat dry eye disease.","indications":["Treatment of dry eye disease"],"catalyst":""},{"name":"Onexton™ Gel","genericName":"Onexton™ Gel","slug":"onexton-gel","phase":"phase_3","mechanism":"Onexton is a topical combination gel containing clindamycin and benzoyl peroxide that reduces acne by killing bacteria and decreasing sebum production.","indications":["Acne vulgaris"],"catalyst":""},{"name":"PART 1: Double-blind Placebo-controlled","genericName":"PART 1: Double-blind Placebo-controlled","slug":"part-1-double-blind-placebo-controlled","phase":"phase_3","mechanism":"This drug is a selective serotonin reuptake inhibitor.","indications":["Major depressive disorder","Generalized anxiety disorder"],"catalyst":""},{"name":"Permethrin 1% rinse","genericName":"Permethrin 1% rinse","slug":"permethrin-1-rinse","phase":"phase_3","mechanism":"Permethrin 1% rinse works by killing or repelling insects and other arthropods through its insecticidal properties.","indications":["Treatment and prevention of head lice infestations","Treatment and prevention of scabies infestations"],"catalyst":""},{"name":"Placebo topical cream","genericName":"Placebo topical cream","slug":"placebo-topical-cream","phase":"marketed","mechanism":"A placebo topical cream contains no active pharmaceutical ingredient and produces therapeutic effects solely through the placebo effect.","indications":[],"catalyst":""},{"name":"SAPHRIS","genericName":"SAPHRIS","slug":"saphris","phase":"marketed","mechanism":"SAPHRIS (asenapine) is an atypical antipsychotic that blocks dopamine and serotonin receptors in the brain to reduce psychotic symptoms and mood disturbances.","indications":["Schizophrenia","Bipolar I disorder (acute manic or mixed episodes)"],"catalyst":""},{"name":"SPIL1033","genericName":"SPIL1033","slug":"spil1033","phase":"phase_3","mechanism":"SPIL1033 is a small molecule drug that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"TA103","genericName":"TA103","slug":"ta103","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Westcort","genericName":"HYDROCORTISONE VALERATE","slug":"hydrocortisone-valerate","phase":"marketed","mechanism":"Glucocorticoid receptor","indications":["Corticosteroid-responsive dermatoses"],"catalyst":""},{"name":"matching placebo injections","genericName":"matching placebo injections","slug":"matching-placebo-injections","phase":"phase_3","mechanism":"Matching placebo injections are used to compare the efficacy of a new drug to a placebo.","indications":["Comparing the efficacy of a new drug to a placebo"],"catalyst":""}],"recentEvents":[{"date":"2024-02-06","type":"earnings","headline":"Sun Pharma Q3 FY2024 Earnings: Net Sales Rise 10% YoY","summary":"Sun Pharmaceutical Industries reported a 10% year-over-year increase in net sales for the third quarter of FY2024, driven by strong growth in the US and international markets.","drugName":"","sentiment":"positive"},{"date":"2023-08-01","type":"deal","headline":"Sun Pharma Acquires US-Based Generic Pharmaceutical Company","summary":"Sun Pharmaceutical Industries has acquired a US-based generic pharmaceutical company, expanding its presence in the US market.","drugName":"","sentiment":"neutral"},{"date":"2022-12-15","type":"regulatory","headline":"FDA Approves Sun Pharma's Generic Version of Topical Cream","summary":"The US FDA has approved Sun Pharmaceutical Industries' generic version of a topical cream, expanding the company's portfolio of generic dermatology products.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMicEFVX3lxTE1EaTJxR1ZoM29WMHBSOUlHQ3J3V1ZjYXloeUhxVG9YSTdpWU1Wd191N0t2SGNfaEhPcE1hMEhzREduWThKUmhWWkl6SVFHR1ZIY3FsY0h3Uks4T2lobXdvZ3lHRUFWQUMycFd5OUU2N1Q?oc=5","date":"2026-04-04","type":"pipeline","source":"Yahoo Finance Singapore","summary":"Makers Laboratories Limited (MAKERSL.BO) Analyst insights, Price targets and Recommendations - Yahoo Finance Singapore","headline":"Makers Laboratories Limited (MAKERSL.BO) Analyst insights, Price targets and Recommendations","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3gFBVV95cUxPdHY1dzZ0Y2dwYmh3RWE3d09ROGRmQWhYOFBRVURDOG9idGx1MnMxbzZfOHowMXFSOVZMNUp1cG9aT1YxeFd0UjFXeXpfV3lQdGRiVm5EU2tZUlZiN3JXV1NKd201TGRyb3dFMmw2dHBNWDVoTUZjVy1jV2VkdWJqMm9ld3hZdDJVWkRjdnBxVEVyZjJRNE9VRjJmc2hwbnM4aDFwWjY4TS1sMlpOWk9KTmhCdTBONlRNbjlwWGlLUzN4VkJKQ1Q1TWZweVRMbTZRUEJESGpxNVl2MnFoNkE?oc=5","date":"2026-03-20","type":"regulatory","source":"Whalesbook","summary":"India's Drugmakers Rush Generic Semaglutide After Patent Expiry - Whalesbook","headline":"India's Drugmakers Rush Generic Semaglutide After Patent Expiry","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3wFBVV95cUxOWHRwTGxhaHZJbk5OQjViVUQ3ZmkwRjdMalNDT1AzOHpSOGdEb29hY21GSmlhWXhrdFFUMFJhOTJzR0Y0RDlkbzduVjZiQVZ4Sy1yODVfTjdQRVctazYtRmg1NmhjWUVCamt2QVhZNk1Wa25hVUFzNHdxVjQ5cUNfcEp4bDVDWDNySkdKZ3g4a0ZSTHVLX2NZLUtFNEY5aVB5WWVGY28wQnZMR1RsV0FUX2NBcXBQWVR1ZWc5enNzOS11M2NHczc1Xzg3NWdEQUl1d3R0UHVGWlVyZTlBUVJ3?oc=5","date":"2026-03-20","type":"regulatory","source":"Whalesbook","summary":"Semaglutide Patent Expiry: India mein Generic Drugs ka Toofan! Prices **70%** tak girne ka chance - Whalesbook","headline":"Semaglutide Patent Expiry: India mein Generic Drugs ka Toofan! Prices **70%** tak girne ka chance","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixwFBVV95cUxQeHlCV0dELWJaQ3JFQi1HeHlvcFpQaDhxN1ROdDBQMlpXR2kydk5FQmNoVm9ZeTZCVkZBWVNvZlZzRnBUWmlLLXMzLXdRS2JkYUhQem1HMHZySzZ2bDlvU0pOLWZwSWlXbHZaLTVreDlkQmVXQ1FSeWhreTFRNUZONDhmd2g3RWppQkdWT3R4bDVZNkhZcUtleFF6NWd2S2RXN0owWlYzSkwySFE5NExDLWxpU014eHA1TTgyNFRtUThoakx1WEY0?oc=5","date":"2026-01-26","type":"pipeline","source":"Reuters","summary":"China halts sale of Sun Pharma drug used to treat dementia - Reuters","headline":"China halts sale of Sun Pharma drug used to treat dementia","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMieEFVX3lxTFA3cTVsei02cDVyLXJxZlV4eXdId043c0YtUWpGYkEyVVNqTi1HNTRnczlCNkVhWXFQbmlFWU03VEkzNG1JYzVZYXJXa3FwcWlfd2tEVEQ5YTR1QkZtblBqU2Q5TFFDUWlQaUxkUkc0anJxX2FZX2V6ag?oc=5","date":"2025-11-25","type":"pipeline","source":"Quiver Quantitative","summary":"Xtrackers Nifty 500 India ETF Holdings - Quiver Quantitative","headline":"Xtrackers Nifty 500 India ETF Holdings","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxNZDdPUVU3NXdYZDFXZjF4OG45YnZYREhoOFRUT0w3UUE0MldRelJ2UHVGYVlxbldSQ3l3MFZfM1NfTm9zMi02Mm5hVVZtYnJ2TE8xUzBoUjFOT1VCZzhHN3VCckRLb3RkRVB1amJZOHdiM3ZlNlhnVHlhc3JnSFEteg?oc=5","date":"2025-11-05","type":"earnings","source":"Yahoo Finance Singapore","summary":"India's Sun Pharma beats Q2 profit estimates, targets growth through drug launches - Yahoo Finance Singapore","headline":"India's Sun Pharma beats Q2 profit estimates, targets growth through drug launches","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxPM25XSHItaEpaODhDS0hhZTliOUZPSUVyM3V5WmFKMHItWEdXWTcyeWs3cDFtZGtoMG05cjFJTFFCdm9wNFZvWGhVQzQyc2IxR3lSb1VZOVJPUmJEY3RnNDFVbWRKcWl0ZC1mcGotbl9ZU0d1X0xqQ3BTM04zQ2hBZVh6TktZazNaYVdLWQ?oc=5","date":"2025-11-04","type":"earnings","source":"Yahoo Finance","summary":"Sun Pharmaceuticals Industries Ltd (NSE:SUNPHARMA) Q2 2026 Earnings Report Preview: What To Expect - Yahoo Finance","headline":"Sun Pharmaceuticals Industries Ltd (NSE:SUNPHARMA) Q2 2026 Earnings Report Preview: What To Expect","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifkFVX3lxTFBSTGVKUXlCNlpEc3VCM0JQMmhYVFV0X05qTm5xUHdFY0lXTTNvVUJLdHhZbmtXZ044R3FEX3dkbkVPS0VkUUxBMk5sTmlDVnFCZVBDRGV3cnhGNG84dklqY0pLazRjaHRLT2Q4czY4bzYxM0dLcUltaW5fYVFwUQ?oc=5","date":"2025-09-09","type":"regulatory","source":"Yahoo Finance Singapore","summary":"US FDA deems Sun Pharma's Halol plant not compliant with its manufacturing rules - Yahoo Finance Singapore","headline":"US FDA deems Sun Pharma's Halol plant not compliant with its manufacturing rules","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixwFBVV95cUxQRXowb0dsOG9BYlhYLVRXbC1SenhYUXpQbWxKbFNiSEZPWUFfXzZRaWh0Rjk2MkJXX0FLZXFFUlg3S0hXS2diZnFWX2J4S1JpRUpfRUtyMGhlZDhvcUhFRXB4amMwWk90OFd5bkU4TzNmOGh3emM5aWNlM2prSEdTQkRuMHR1ekl1MThVR0hFRWlDcnZsRWtzcDlrd3NfLXpfVFBfbkVLbWVsVHV6c0FhcGNHZFdfeUZidHBBOThJZ1k0WEQ3V3Jn?oc=5","date":"2025-06-13","type":"pipeline","source":"Reuters","summary":"India's Sun Pharma names Kirti Ganorkar as managing director - Reuters","headline":"India's Sun Pharma names Kirti Ganorkar as managing director","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxNUnJTdFZrT3NqamVZOGlINGVia25lempQYnRTZFlSczhreFY2ekktVXJQbFNiblBITHJoR19CX0R4c2htNGlpRElQaFV2SjJOWGpKM0g1aFJIUWhNMmRWb3dTNGc5SDBCVW5yN2VnMndHZHZnLXd2Q1o4LU9VcmdfTzBwWUNDQTlZMUp2SU5GRVBtTk41cUc0TnN3dWppZmZzLWM4RnhWWVVodUcxVVRvemoxaFlqZzE5?oc=5","date":"2025-02-19","type":"pipeline","source":"Reuters","summary":"Indian pharma stocks drop on Trump's tariff plans - Reuters","headline":"Indian pharma stocks drop on Trump's tariff plans","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiaEFVX3lxTE1LSWhWdXdkU2RBQXFHeXQwak45NFpsRXpqQkktTlBGeWZUeHoydEhrLU5WaG5yOGdiQl9uX3E1MUI0MG1IT3dSN2o0aEV4Sngza0k2WU1vRkhwYjZkNnNrLTZzalhZNmkw?oc=5","date":"2024-06-24","type":"deal","source":"BioSpace","summary":"Sun Pharma Completes Taro Merger - BioSpace","headline":"Sun Pharma Completes Taro Merger","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE1TbTM3dmFZdFNDRmsyZDdoV1VPcWNCWnhDZmFDUUVxcUROaTB2UlNoS2dnNUc0aFZ5VmlxVkh6UkR5aWlONldvVWVZTlNYdGpzX3BF?oc=5","date":"2020-12-07","type":"deal","source":"StockInvest.us","summary":"Sun Pharmaceutical Industries Stock Price Forecast. Should You Buy SUNPHARMA.NS? - StockInvest.us","headline":"Sun Pharmaceutical Industries Stock Price Forecast. Should You Buy SUNPHARMA.NS?","sentiment":"neutral"}],"patents":[{"drugName":"Loratadine","drugSlug":"loratadine","patentNumber":"","type":"Patent Cliff","expiryDate":"2025-06-01","territory":"US","annualRevenue":150000000},{"drugName":"Levocetirizine","drugSlug":"levocetirizine","patentNumber":"","type":"Patent Cliff","expiryDate":"2027-06-01","territory":"US","annualRevenue":200000000}],"drugCount":40,"phaseCounts":{"marketed":14,"phase_3":15,"phase_2":8,"phase_1":3},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Aurobindo Pharma","Dr. Reddy's Laboratories","Cipla Ltd"],"therapeuticFocus":["Dermatology","Cardiovascular","Central Nervous System"],"financials":null,"yahoo":{"currentPrice":1714.6,"previousClose":1718,"fiftyTwoWeekHigh":1851.2,"fiftyTwoWeekLow":1548,"fiftyTwoWeekRange":"1548.0 - 1851.2","fiftyDayAverage":1733.2,"twoHundredDayAverage":1697.87,"beta":0.11,"enterpriseValue":3910426427392,"forwardPE":30.2,"priceToBook":5.28,"priceToSales":7.24,"enterpriseToRevenue":6.88,"enterpriseToEbitda":24.4,"pegRatio":0,"ebitda":160245776384,"ebitdaMargin":28.2,"freeCashflow":0,"operatingCashflow":0,"totalDebt":52151001088,"debtToEquity":6.7,"currentRatio":0,"returnOnAssets":0,"returnOnEquity":0,"analystRating":"1.6 - Buy","recommendationKey":"buy","numberOfAnalysts":36,"targetMeanPrice":1961.56,"targetHighPrice":2392,"targetLowPrice":1550,"dividendRate":16.5,"payoutRatio":0.35,"fiveYearAvgDividendYield":0.93,"exDividendDate":1770249600,"insiderHeldPercent":55.6,"institutionHeldPercent":28.7,"sharesOutstanding":2399334970,"floatShares":1068009022,"sharesShort":0,"shortRatio":0,"shortPercentOfFloat":0,"epsTrailing":45.53,"epsForward":56.73,"revenuePerShare":236.56,"bookValue":324.46,"officers":[{"age":70,"name":"Mr. Dilip Shantilal Shanghvi","title":"Executive Chairman of the Board"},{"age":41,"name":"Mr. Aalok Dilip Shanghvi","title":"COO, Head of Global Generics R&D, Business Devp., and Whole Time Director"},{"age":58,"name":"Mr. Kirti Wardhaman Ganorkar","title":"Managing Director"},{"age":57,"name":"Ms. Jayashree  Satagopan","title":"Executive VP & CFO"},{"age":54,"name":"Mr. Dheeraj Prasad Sinha BE","title":"EVP & Chief Information Officer"},{"age":null,"name":"Dr. Abhishek  Sharma","title":"VP, Head of Investor Relations & Strategic Projects"},{"age":null,"name":"Mr. Anoop  Deshpande","title":"Company Secretary & Compliance Officer"},{"age":71,"name":"Mr. Kalyanasundaram  Subramanian","title":"Director of Corporate Development"}],"industry":"Drug Manufacturers - Specialty & Generic","irWebsite":"","website":"https://sunpharma.com","phone":"91 22 4324 4324"}}